Fulgent GeneticsMEX:FLGT 64 Operating Margin % is -48.67% as of Mar. 2026. GuruFocus rates MEX:FLGT with a GF Score™ of 64/100 and a GF Value™ of MXN411.80 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Fulgent Genetics ranks worse than 73.04% on this metric.
The historical rank and industry rank for Fulgent Genetics's Operating Margin % or its related term are showing as below:
MEX:FLGT'
s Operating Margin % Range Over the Past 10 Years
Min: -33.07 Med: -9.96 Max: 68.8
Current: -33.07
MEX:FLGT's Operating Margin % is ranked worse than 73.04% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.195
vs MEX:FLGT: -33.07
Fulgent Genetics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Fulgent Genetics Operating Margin % Related Terms
Fulgent Genetics Operating Margin % Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:FLGT vs CSTL, MYGN, PRE: Operating Margin % Comparison
For the Diagnostics & Research subindustry, Fulgent Genetics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Fulgent Genetics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics (MEX:FLGT) has a Operating Margin % of -48.67% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Fulgent Genetics and its competitors. According to the industry distribution chart, Fulgent Genetics ranks #149 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 73%.
Is Fulgent Genetics' Operating Margin % too high?
Fulgent Genetics' current Operating Margin % is -48.67%. Based on the distribution chart, Fulgent Genetics ranks #149 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Fulgent Genetics has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Operating Margin % compare to CSTL and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #149 out of 204 companies for Operating Margin %. This places Fulgent Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Fulgent Genetics and its competitors. Fulgent Genetics's current Operating Margin % is -48.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (MEX:FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN411.80, compared to a current price of MXN312.50 — trading 24.1% below its estimated fair value. The current Operating Margin % is -48.67%. Fulgent Genetics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Fulgent Genetics (MEX:FLGT), the current Operating Margin % is -48.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (MEX:FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of MXN312.50 is trading 24.1% below its estimated GF Value™ of MXN411.80.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for MEX:FLGT:
Operating Margin %: -48.67%
GF Value™: MXN411.80 vs. price of MXN312.50 (24.1% below fair value)
No single metric tells the full story. See the MEX:FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
64GF Score
Get the complete analysis for MEX:FLGT
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:FLGT has been successfully added to your 
